Nonmyeloablative Allogeneic Stem-Cell Transplantation for Metastatic Renal Cell Cancer: A Review and Update
Metastatic renal cell carcinoma (RCC) is resistant to conventional chemotherapy and radiotherapy. However, immunotherapy appears to be effective in 15—20% of cases, with interleukin-2 becoming the standard therapy for this disease. As a consequence of the immune susceptibility of RCC, other avenues...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2006-01-01
|
| Series: | The Scientific World Journal |
| Online Access: | http://dx.doi.org/10.1100/tsw.2006.391 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850164233416736768 |
|---|---|
| author | P. Erotocritou H. Ahmed S.S. Patel I. Shergill H.R. Patel P.M. Shah M. Arya |
| author_facet | P. Erotocritou H. Ahmed S.S. Patel I. Shergill H.R. Patel P.M. Shah M. Arya |
| author_sort | P. Erotocritou |
| collection | DOAJ |
| description | Metastatic renal cell carcinoma (RCC) is resistant to conventional chemotherapy and radiotherapy. However, immunotherapy appears to be effective in 15—20% of cases, with interleukin-2 becoming the standard therapy for this disease. As a consequence of the immune susceptibility of RCC, other avenues of immunotherapy are being explored, such as nonmyeloablative allogeneic stem cell transplantation (NST). A number of trials have shown NST to be effective in varying degrees, causing partial or complete regression. Although nonmyeloablative conditioning is safer than myeloablative conditioning, its role has yet to be clearly proven as many studies have shown variable effect. Alongside this limitation, transplant-related toxicity also forms obstacles. Regardless of the limitation of NST, further refinement of the technique, with appropriate patient selection, may lead to this being an effective therapeutic choice for a significant number of individuals. |
| format | Article |
| id | doaj-art-eb01c9d324bb4fbba1e0206f96968ef0 |
| institution | OA Journals |
| issn | 1537-744X |
| language | English |
| publishDate | 2006-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | The Scientific World Journal |
| spelling | doaj-art-eb01c9d324bb4fbba1e0206f96968ef02025-08-20T02:22:02ZengWileyThe Scientific World Journal1537-744X2006-01-0162519252810.1100/tsw.2006.391Nonmyeloablative Allogeneic Stem-Cell Transplantation for Metastatic Renal Cell Cancer: A Review and UpdateP. Erotocritou0H. Ahmed1S.S. Patel2I. Shergill3H.R. Patel4P.M. Shah5M. Arya6The Institute of Urology and Nephrology, University College London, U.K. and The Gujarat Cancer and Research Institute, MP Shah Cancer Hospital, Ahmedabad, IndiaThe Institute of Urology and Nephrology, University College London, U.K. and The Gujarat Cancer and Research Institute, MP Shah Cancer Hospital, Ahmedabad, IndiaThe Institute of Urology and Nephrology, University College London, U.K. and The Gujarat Cancer and Research Institute, MP Shah Cancer Hospital, Ahmedabad, IndiaThe Institute of Urology and Nephrology, University College London, U.K. and The Gujarat Cancer and Research Institute, MP Shah Cancer Hospital, Ahmedabad, IndiaThe Institute of Urology and Nephrology, University College London, U.K. and The Gujarat Cancer and Research Institute, MP Shah Cancer Hospital, Ahmedabad, IndiaThe Institute of Urology and Nephrology, University College London, U.K. and The Gujarat Cancer and Research Institute, MP Shah Cancer Hospital, Ahmedabad, IndiaThe Institute of Urology and Nephrology, University College London, U.K. and The Gujarat Cancer and Research Institute, MP Shah Cancer Hospital, Ahmedabad, IndiaMetastatic renal cell carcinoma (RCC) is resistant to conventional chemotherapy and radiotherapy. However, immunotherapy appears to be effective in 15—20% of cases, with interleukin-2 becoming the standard therapy for this disease. As a consequence of the immune susceptibility of RCC, other avenues of immunotherapy are being explored, such as nonmyeloablative allogeneic stem cell transplantation (NST). A number of trials have shown NST to be effective in varying degrees, causing partial or complete regression. Although nonmyeloablative conditioning is safer than myeloablative conditioning, its role has yet to be clearly proven as many studies have shown variable effect. Alongside this limitation, transplant-related toxicity also forms obstacles. Regardless of the limitation of NST, further refinement of the technique, with appropriate patient selection, may lead to this being an effective therapeutic choice for a significant number of individuals.http://dx.doi.org/10.1100/tsw.2006.391 |
| spellingShingle | P. Erotocritou H. Ahmed S.S. Patel I. Shergill H.R. Patel P.M. Shah M. Arya Nonmyeloablative Allogeneic Stem-Cell Transplantation for Metastatic Renal Cell Cancer: A Review and Update The Scientific World Journal |
| title | Nonmyeloablative Allogeneic Stem-Cell Transplantation for Metastatic Renal Cell Cancer: A Review and Update |
| title_full | Nonmyeloablative Allogeneic Stem-Cell Transplantation for Metastatic Renal Cell Cancer: A Review and Update |
| title_fullStr | Nonmyeloablative Allogeneic Stem-Cell Transplantation for Metastatic Renal Cell Cancer: A Review and Update |
| title_full_unstemmed | Nonmyeloablative Allogeneic Stem-Cell Transplantation for Metastatic Renal Cell Cancer: A Review and Update |
| title_short | Nonmyeloablative Allogeneic Stem-Cell Transplantation for Metastatic Renal Cell Cancer: A Review and Update |
| title_sort | nonmyeloablative allogeneic stem cell transplantation for metastatic renal cell cancer a review and update |
| url | http://dx.doi.org/10.1100/tsw.2006.391 |
| work_keys_str_mv | AT perotocritou nonmyeloablativeallogeneicstemcelltransplantationformetastaticrenalcellcancerareviewandupdate AT hahmed nonmyeloablativeallogeneicstemcelltransplantationformetastaticrenalcellcancerareviewandupdate AT sspatel nonmyeloablativeallogeneicstemcelltransplantationformetastaticrenalcellcancerareviewandupdate AT ishergill nonmyeloablativeallogeneicstemcelltransplantationformetastaticrenalcellcancerareviewandupdate AT hrpatel nonmyeloablativeallogeneicstemcelltransplantationformetastaticrenalcellcancerareviewandupdate AT pmshah nonmyeloablativeallogeneicstemcelltransplantationformetastaticrenalcellcancerareviewandupdate AT marya nonmyeloablativeallogeneicstemcelltransplantationformetastaticrenalcellcancerareviewandupdate |